CN116355804A - Lactobacillus reuteri for treating polycystic ovary syndrome and application thereof - Google Patents
Lactobacillus reuteri for treating polycystic ovary syndrome and application thereof Download PDFInfo
- Publication number
- CN116355804A CN116355804A CN202310370659.5A CN202310370659A CN116355804A CN 116355804 A CN116355804 A CN 116355804A CN 202310370659 A CN202310370659 A CN 202310370659A CN 116355804 A CN116355804 A CN 116355804A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus reuteri
- lactobacillus
- ovary syndrome
- polycystic ovary
- preservation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000186604 Lactobacillus reuteri Species 0.000 title claims abstract description 44
- 229940001882 lactobacillus reuteri Drugs 0.000 title claims abstract description 43
- 201000010065 polycystic ovary syndrome Diseases 0.000 title claims abstract description 38
- 239000003613 bile acid Substances 0.000 claims abstract description 25
- 238000004321 preservation Methods 0.000 claims abstract description 17
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims abstract description 14
- 229940088597 hormone Drugs 0.000 claims abstract description 10
- 239000005556 hormone Substances 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 17
- 230000001580 bacterial effect Effects 0.000 claims description 17
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 16
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 14
- 102000009151 Luteinizing Hormone Human genes 0.000 claims description 9
- 108010073521 Luteinizing Hormone Proteins 0.000 claims description 9
- 239000002054 inoculum Substances 0.000 claims description 9
- 229940040129 luteinizing hormone Drugs 0.000 claims description 9
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 8
- 239000002131 composite material Substances 0.000 claims description 8
- 239000001963 growth medium Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000000186 progesterone Substances 0.000 claims description 8
- 229960003387 progesterone Drugs 0.000 claims description 8
- 239000003223 protective agent Substances 0.000 claims description 8
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 7
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 claims description 7
- 229930182833 estradiol Natural products 0.000 claims description 7
- 229960005309 estradiol Drugs 0.000 claims description 7
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 claims description 7
- 230000000813 microbial effect Effects 0.000 claims description 7
- 229960003604 testosterone Drugs 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 4
- 230000003054 hormonal effect Effects 0.000 claims description 4
- 239000002609 medium Substances 0.000 claims description 4
- 230000031200 bile acid secretion Effects 0.000 claims description 3
- 239000002068 microbial inoculum Substances 0.000 claims description 3
- 238000009629 microbiological culture Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 241001052560 Thallis Species 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 239000006872 mrs medium Substances 0.000 claims description 2
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 230000000875 corresponding effect Effects 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 244000005709 gut microbiome Species 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 7
- 102000003946 Prolactin Human genes 0.000 description 7
- 108010057464 Prolactin Proteins 0.000 description 7
- 210000004246 corpus luteum Anatomy 0.000 description 7
- 229940097325 prolactin Drugs 0.000 description 7
- 230000002611 ovarian Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010066 hyperandrogenism Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- BHTRKEVKTKCXOH-AYSJQVDDSA-N taurochenodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-AYSJQVDDSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 208000002352 blister Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- -1 cysteine amino acid salt Chemical class 0.000 description 2
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000007984 Female Infertility Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010021928 Infertility female Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- PYMYPHUHKUWMLA-VAYJURFESA-N aldehydo-L-arabinose Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-VAYJURFESA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 208000015124 ovarian disease Diseases 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000543 ovarian dysfunction Toxicity 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 235000019722 synbiotics Nutrition 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides lactobacillus reuteri for treating polycystic ovary syndrome and application thereof, the specific name of the lactobacillus reuteri is lactobacillus reuteri Lactobacillus reuteri LR, the preservation number is CGMCC No.24409, the hormone level in mice suffering from polycystic ovary syndrome can be adjusted back to the normal level, the content of bile acid is increased, the related symptoms of polycystic ovary syndrome are relieved, the effect of the lactobacillus reuteri is obviously better than that of other strains, and the lactobacillus reuteri can be used for preparing medicines with corresponding effects.
Description
Technical Field
The invention belongs to the technical field of microorganisms, and relates to lactobacillus reuteri for treating polycystic ovary syndrome and application thereof.
Background
Polycystic ovary syndrome (PCOS) is a common heterogeneous endocrine disorder with high morbidity in women of global childbearing age. This disease is the leading cause of female infertility, which is defined as a combination of ovarian dysfunction, follicular maturation disorders and ovarian hormonal regulation disorders, manifested by hyperandrogenism and Luteinizing Hormone (LH) hypersecretion. PCOS patients exhibit cystic follicular accumulation, increased ovarian matrix thickness, reduced corpus luteum, and a concomitant loosening of ovarian granulosa cells. Intestinal microbiota has been shown to be a critical requirement for maintaining host health, including metabolic homeostasis, immunity, and intestinal barrier function.
Dysbiosis of the gut microbiota is associated with the progression of PCOS. Compared to healthy females, PCOS patients have reduced intestinal microbiologic diversity, accompanied by changes in specific relative abundance, bacteroidetes and firmicutes. Alterations in intestinal microbiota are associated with PCOS female hyperandrogenism, suggesting a potential role for testosterone in the structure of the intestinal microbiota. Bile acids are cholesterol-derived endogenous metabolites produced in the liver. Primary bile acids are direct products of cholesterol catabolism, act as substrates for enzymes from the intestinal flora, and are then converted to secondary bile acids, which are returned to the liver through the intestinal hepatic circulation. The link between bile acids, intestinal microbiota and metabolic disorders means that bile acids can be involved in regulating PCOS-related metabolic disorders. KEGG analysis indicated that PCOS women had altered bile acid metabolic pathways. The circulating binding primary bile acid levels in PCOS individuals are increased, which is positively correlated with hyperandrogenism. These data indicate that improving intestinal microbiota and bile acid metabolism may be a promising approach to treating PCOS.
The nutritional intervention of probiotics, prebiotics or synbiotics is an effective method to improve intestinal microbiota and metabolic diseases, but the relationship between probiotics, intestinal microbiota-bile acid axis and PCOS is still poorly understood in the art, and whether or not PCOS symptoms can be alleviated by probiotics, which still requires further investigation by the person skilled in the art.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide lactobacillus reuteri for treating polycystic ovary syndrome and application thereof.
In order to achieve the aim of the invention, the invention adopts the following technical scheme:
in a first aspect, the invention provides lactobacillus reuteri for treating polycystic ovary syndrome, the specific name of the lactobacillus reuteri is lactobacillus reuteri (Lactobacillus reuteri) LR10, the preservation unit is China general microbiological culture Collection center (CGMCC) with the preservation number of CGMCC No.24409, the preservation date of 2022 is 02 month 21, and the preservation address of Beichen Xiyun No.1 hospital 3 in the Chaoyang area of Beijing city.
In a second aspect, the invention provides a lactobacillus reuteri LR10 inoculant, which is prepared by a method comprising the following steps: inoculating the lactobacillus reuteri LR10 according to the first aspect into a culture medium and culturing at 35-40 ℃.
Specific values of the above 35-40deg.C include 35deg.C, 36deg.C, 37deg.C, 38deg.C, 39deg.C, 40deg.C, etc.
Preferably, the medium includes an MRS medium.
Preferably, the components in the MRS culture medium comprise 8-12g/L peptone, 8-12g/L beef extract, 15-20g/L glucose, 1-3g/L sodium acetate, 2-6g/L yeast powder, 1-3g/L, K diammonium hydrogen citrate 2 HPO 4 1-3g/L、MgSO 4 0.02-0.2g/L、MnSO 4 0.01-0.1g/L or cysteine amino acid salt 0.1-1g/L or a combination of at least two.
Specific values among the above 8 to 12g/L are, for example, 8g/L, 9g/L, 10g/L, 11g/L, 12g/L, etc.
Specific values among the above 15 to 20g/L are, for example, 15g/L, 16g/L, 17g/L, 18g/L, 19g/L, 20g/L, etc.
Specific values among the above 1 to 3g/L are, for example, 1g/L, 1.2g/L, 1.5g/L, 1.7g/L, 2g/L, 2.2g/L, 2.5g/L, 2.7g/L, 3g/L, etc.
Specific values among the above 2 to 6g/L are, for example, 2g/L, 2.5g/L, 3g/L, 3.5g/L, 4g/L, 4.5g/L, 5g/L, 5.5g/L, 6g/L, etc.
Specific values among the above 0.02 to 0.2g/L are, for example, 0.02g/L, 0.04g/L, 0.06g/L, 0.08g/L, 0.1g/L, 0.12g/L, 0.14g/L, 0.16g/L, 0.18g/L, 0.2g/L, etc.
Specific values among the above 0.01 to 0.1g/L are, for example, 0.01g/L, 0.02g/L, 0.03g/L, 0.04g/L, 0.05g/L, 0.06g/L, 0.07g/L, 0.08g/L, 0.09g/L, 0.1g/L, etc.
Specific values among the above 0.1 to 1g/L are, for example, 0.1g/L, 0.2g/L, 0.3g/L, 0.4g/L, 0.5g/L, 0.6g/L, 0.7g/L, 0.8g/L, 0.9g/L, 1g/L, etc.
Preferably, the incubation time is 18-24 hours, e.g., 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, etc.
Preferably, centrifugation is further included after the culturing, and the bacterial cells are collected.
Preferably, the rotational speed of the centrifugation is 700-1500rpm, and the centrifugation time is 5-15min.
Preferably, the method further comprises mixing the bacterial cells with a protective agent, wherein the protective agent comprises glycerol.
In a third aspect, the invention provides a composite microbial agent, which comprises lactobacillus reuteri LR10 and lactobacillus gasseri (Lactobacillus gasseri) LG08 according to the first aspect, wherein the preservation number of the lactobacillus gasseri LG08 is CGMCC No.16131, the preservation date is 2018, month 07 and 18, the preservation address is North Chen West Luo No.1, no. 3 in the Korean region of Beijing city, and the preservation unit is China general microbiological culture Collection center.
Preferably, the ratio of the number of viable bacteria of the lactobacillus reuteri LR10 to the number of viable bacteria of the lactobacillus gasseri LG08 is (1-9): 1-3.
Specific values in the above (1-9) are, for example, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, etc.
Specific values in the above (1-3) are, for example, 1, 1.2, 1.5, 1.7, 2, 2.2, 2.5, 2.7, 3, etc.
Preferably, the composite microbial agent further comprises a protective agent, and the protective agent comprises glycerol.
In a fourth aspect, the present invention provides the use of lactobacillus reuteri LR10 as described in the first aspect, a lactobacillus reuteri LR10 bacterial agent as described in the second aspect or a complex bacterial agent as described in the third aspect in the manufacture of a medicament for the treatment/alleviation of polycystic ovary syndrome.
In a fifth aspect, the present invention provides the use of lactobacillus reuteri LR10 as defined in the first aspect, a lactobacillus reuteri LR10 inoculant as defined in the second aspect or a complex inoculant as defined in the third aspect for the manufacture of a medicament for modulating a hormonal disorder comprising any one or a combination of at least two of testosterone, luteinizing hormone, progesterone, estradiol or prolactin.
Preferably, the modulation of hormonal disorders comprises any one or a combination of at least two of lowering testosterone levels, lowering luteinizing hormone levels, increasing progesterone levels, increasing estradiol levels, or increasing prolactin levels.
The hormone-modulating drugs may be administered orally or by injection into animal models for use in basic studies related to testosterone, luteinizing hormone, progesterone, estradiol or prolactin.
In a sixth aspect, the present invention provides the use of lactobacillus reuteri LR10 as described in the first aspect, a lactobacillus reuteri LR10 inoculant as described in the second aspect or a complex inoculant as described in the third aspect for the manufacture of a medicament for promoting bile acid secretion, said bile acid comprising any one or a combination of at least two of lithocholic acid, taurocholic acid or tauchenodeoxycholic acid.
The medicine for promoting bile acid secretion can be applied to animal models orally or by injection for use in basic research related to lithocholic acid, taurocholic acid or taurochenodeoxycholic acid secretion.
The numerical ranges recited herein include not only the recited point values, but also any point values between the recited numerical ranges that are not recited, and are limited to, and for the sake of brevity, the invention is not intended to be exhaustive of the specific point values that the recited range includes.
Compared with the prior art, the invention has the following beneficial effects:
the invention firstly screens to obtain a strain which can be used for treating polycystic ovary syndrome: lactobacillus reuteri LR10, and its efficacy was verified by animal experiments:
the bile acid metabolic pathway is a potential mechanism between the gut microbiota and PCOS. Intestinal microbiota has a variety of metabolic functions including the ability to synthesize, metabolize and reabsorption bile acids. Quantitative analysis of bile acids by animal model experiments has been found that supplementation with probiotics reverses the bile acid levels in PCOS mice. The hormone content in the mice with polycystic ovary syndrome is seriously unbalanced, a large number of saccular follicles appear, the corpus luteum number is reduced, and the content of bile acids in the liver is greatly reduced; the LR10 intervention can obviously regulate hormone level (the content of total testosterone and luteinizing hormone is regulated downwards, the content of progesterone, estradiol and prolactin is regulated upwards), the content of each bile acid (lithocholic acid, sodium taurocholate and tauchenodeoxycholic acid) is also obviously improved, the number of saccular follicles in polycystic lesions is obviously reduced, the corpus luteum is increased, the related symptoms of polycystic ovary syndrome are obviously relieved, and the effect is obviously better than other strains.
In addition, LG08 has a relatively remarkable effect on alleviating polycystic ovary syndrome, but is slightly worse than LR10, but after being compounded with LR10, the effect is better than that of single strain LR10, probably because the two strains can mutually promote the growth and metabolic activities of each other, so that the synergistic effect is achieved in the aspects of callback hormone level, increasing the content of bile acid in liver and treating polycystic ovary syndrome.
Detailed Description
The technical scheme of the invention is further described by the following specific embodiments. It will be apparent to those skilled in the art that the examples are merely to aid in understanding the invention and are not to be construed as a specific limitation thereof.
In the following examples, all reagents and consumables were purchased from the reagent manufacturers routine in the art unless specifically indicated; unless otherwise indicated, all methods and techniques used are those conventional in the art.
Example 1
The present example performs strain screening:
selecting a collected fermented sausage sample of Jintang county in Sichuan province, performing 10 times gradient dilution by using physiological saline with the mass concentration of 0.9%, diluting for 3 times, coating on an MRS solid culture medium, culturing at 37 ℃ for 72 hours, selecting 3 strains of bacteria with different forms, marking and purifying on the surface of the MRS solid culture medium, selecting single bacterial colonies, performing expansion culture by using the MRS liquid culture medium at 37 ℃, and then preserving by using glycerol with the mass concentration of 40%. And (3) screening in vitro physiological characteristics test aiming at the preserved 3 single strains, selecting a single strain with resistance (in vitro artificial simulation) to low pH and bile salt, strong adhesion capability of gastrointestinal epithelial cells and optimal antibacterial capability, and adding a cryoprotectant into a biological refrigerator at-80 ℃ for preservation.
Example 2
This example carries out 16S rRNA molecular biology identification and physicochemical property analysis on the optimal single strain selected in example 1:
the deposited strain was removed, inoculated at a ratio of 3% into a centrifuge tube containing 30mL of MRS liquid medium, cultured at 37℃for 24 hours, centrifuged (10000 rpm,5 min), and the supernatant was removed to collect the cells. Extracting genome of the strain, adding bacterial universal primer and sterile water for PCR amplification, and sending the amplified product to China academy of sciences microbiological study for sequencing and identification. The sequence of the 16S rDNA of the strain after sequencing analysis is shown as SEQ ID No. 1. The sequence was subjected to nucleic acid sequence alignment in GeneBank, and the result shows that the strain is Lactobacillus reuteri, and is named Lactobacillus reuteri LR10.
SEQ ID No.1：
ATACATGCAAGTCGTACGCACTGGCCCAACTGATTGATGGTGCTTGCACCTGATTGACGATGGATCACCAGTGAGTGGCGGACGGGTGAGTAACACGTAGGTAACCTGCCCCGGAGCGGGGGATAACATTTGGAAACAGATGCTAATA
CCGCATAACAACAAAAGCCACATGGCTTTTGTTTGAAAGATGGCTTTGGCT
ATCACTCTGGGATGGACCTGCGGTGCATTAGCTAGTTGGTAAGGTAACGGC
TTACCAAGGCGATGATGCATAGCCGAGTTGAGAGACTGATCGGCCACAAT
GGAACTGAGACACGGTCCATACTCCTACGGGAGGCAGCAGTAGGGAATCT
TCCACAATGGGCGCAAGCCTGATGGAGCAACACCGCGTGAGTGAAGAAG
GGTTTCGGCTCGTAAAGCTCTGTTGTTGGAGAAGAACGTGCGTGAGAGTA
ACTGTTCACGCAGTGACGGTATCCAACCAGAAAGTCACGGCTAACTACGT
GCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTATCCGGATTTATTGG
GCGTAAAGCGAGCGCAGGCGGTTGCTTAGGTCTGATGTGAAAGCCTTCGG
CTTAACCGAAGAAGTGCATCGGAAACCGGGCAACTTGAGTGCAGAAGAG
GACAGTGGAACTCCATGTGTAGCGGTGGAATGCGTAGATATATGGAAGAA
CACCAGTGGCGAAGGCGGCTGTCTGGTCTGCAACTGACGCTGAGGCTCG
AAAGCATGGGTAGCGAACAGGATTAGATACCCTGGTAGTCCATGCCGTAA
ACGATGAGTGCTAGGTGTTGGAGGGTTTCCGCCCTTCAGTGCCGGAGCTA
ACGCATTAAGCACTCCGCCTGGGGAGTACGACCGCAAGGTTGAAACTCAA
AGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGA
AGCTACGCGAAGAACCTTACCAGGTCTTGACATCTTGCGCTAACCTTAGA
GATAAGGCGTTCCCTTCGGGGACGCAATGACAGGTGGTGCATGGTCGTCG
TCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCC
TTGTTACTAGTTGCCAGCATTAAGTTGGGCACTCTAGTGAGACTGCCGGTG
ACAAACCGGAGGAAGGTGGGGACGACGTCAGATCATCATGCCCCTTATGA
CCTGGGCTACACACGTGCTACAATGGACGGTACAACGAGTCGCAAGCTCG
CGAGAGTAAGCTAATCTCTTAAAGCCGTTCTCAGTTCGGACTGTAGGCTGC
AACTCGCCTACACGAAGTCGGAATCGCTAGTAATCGCGGATCAGCATGCC
GCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGGG
AGTTTGTAACGCCCAAAGTCGGTGGCCTAACCATTATGGAGGGAGCCGCCTAAGGCGGGACAGATGACTGGGGTGAAGTCGTAACAAG。
The carbon source utilization capacity of the test strain was determined by performing a sugar fermentation reaction interpretation using an API 50CHL medium (basal medium consisting of API 50CH test strips of 48 fermentable carbohydrates) and an API 50CH test strip according to the API bacteria identification standard. The principle of the method is that the strain to be measured is used for preparing suspension, the suspension is inoculated in each test strip small tube, and after the culture, the carbon source tube which can be utilized can produce acid due to fermentation, and the pH value is reduced, so that the indicator changes color.
As a result, lactobacillus reuteri LR10 can use the carbon source: l-arabinose, D-ribose, D-galactose, D-glucose, maltose, lactose, melibiose, sucrose, raffinose and gluconate.
Example 3
This example explores the effect of lactobacillus reuteri LR10 on the alleviation of polycystic ovary syndrome:
four weeks of large, non-mated female CIR mice (supplied by Shanghai laboratory animal center) were randomly divided into PCOS and control groups after one week in a 12:12 light-dark cycle in a temperature-controlled room (22.+ -. 2 ℃). The control group (n=10) was injected daily with soybean oil vehicle. The PCOS group subcutaneously injected DHEA (dehydroepiandrosterone, 6mg/100g body weight) dissolved in soybean oil for 20 consecutive days to establish a PCOS animal model. PCOS mice exhibited no cycle/irregular ovarian cycle, which were randomly divided into 5 groups of 10: the stomach was irrigated for 24 consecutive days according to the following administration mode.
A model group; no administration;
LR10 group; LR10 bacteria (LR 10 viable count is 200CFU/100g body weight) is infused into stomach once a day;
LG08 group: LG08 bacteria (LG 08 viable count is 200CFU/100g body weight) are irrigated into stomach once a day;
lr10+lg08 group: the composite bacterial agent (the ratio of LR10 to LG08 viable count is 2:1, the total viable count is 200CFU/100g body weight) is irrigated into the stomach once a day;
lr10+ lactobacillus griseus ATCC 19992: the composite bacterial agent (the ratio of LR10 to ATCC 19992 viable count is 2:1, the total viable count is 200CFU/100g body weight) is subcutaneously injected once a day;
the preparation method of the single microbial inoculum comprises the following steps: inoculating (inoculum size 2%) strain (LR 10, LG08 or ATCC 19992) in MRS culture medium, and culturing at 37deg.C for 22 hr to obtain culture solution; centrifuging (1000 rpm,8 min) to obtain each thallus; the thalli are dissolved in a protective agent (the solute in the protective agent is glycerin with the mass concentration of 10 percent, and the solvent is purified water) so as to obtain the corresponding single microbial inoculum.
And mixing the single microbial agents according to the requirements to obtain the composite microbial agent.
The viable cell count detection method refers to: national standard "GB 4789.35-2016 food safety national Standard food microbiology detection lactic acid bacteria detection".
MRS culture medium formula: 9.00g/L peptone, 8.50g/L beef extract, 16.00g/L glucose, 1.50g/L sodium acetate, 3.60g/L yeast powder, 1.30g/L, K diammonium citrate 2 HPO 4 ·3H 2 O 2.00g/L、MgSO 4 ·7H 2 O 0.10g/L、MnSO 4 0.03g/L and 0.20g/L of cysteine amino acid salt are dissolved by deionized water, 1.50mL of Tween 80 is added, the volume is fixed to 1L, and the culture dish is poured into a sterilized culture dish for standby after sterilization and cooling.
At the end of the study, mice were sacrificed after blood collection. Ovariectomy, liver was used for further analysis.
(1) Determination of the content of serotonin
A0.5 mL blood sample from each mouse was centrifuged at 1000g for 15 minutes at 4℃to collect serum, and the serum was kept at 20 ℃. The respective hormone content in the serum samples was measured using the corresponding ELISA kit (Cloud-Clone Corp, houston, TX, USA): the average values of the groups were calculated for Progesterone (PROG), estradiol (E2), total testosterone (T), luteinizing Hormone (LH) and Prolactin (PRO) and are listed in table 1.
TABLE 1
(2) Ovarian vesicular follicle count
Mice were dissected to collect bilateral ovaries, observed for ovarian polycystic lesions, counted for corpus luteum, bleb follicles, and average number of corpus luteum and bleb follicles between each group compared, and the results are shown in table 2.
TABLE 2
(3) Analysis of bile acid content in liver
And (3) quantitatively analyzing the content of various bile acids in the liver by utilizing LC/MS, extracting fatty acids in the liver tissue of the mice to be detected, and loading the sample into the LC/MS after methyl esterification treatment. LC/MS was performed using a Acquity UPLC BEH C18 column. The sample injection volume was 5. Mu.L and the column temperature was 40 ℃. The mobile phase consists of phase a: formic acid (0.01% aqueous solution) and phase B: acetonitrile composition, flow rate 0.25mL/min. After gradient elution, the samples were analyzed by mass spectrometer in a Multiple Reaction Mode (MRM) with negative electrospray ionization. Obtaining the content of each bile acid: lithocholic acid (LCA), taurocholic acid (TLCA), taurochenodeoxycholic acid (TCDCA) are shown in table 3.
TABLE 3 Table 3
Displaying results; compared with healthy mice in a control group, the mice with polycystic ovary syndrome in a model group have serious unbalance of the hormone content, a large number of saccular follicles appear, the corpus luteum number is reduced, and the content of bile acids in the liver is greatly reduced; after the intervention of single bacterial agent or combined bacterial agent, the hormone level can be obviously regulated (the hormone content of progesterone, estradiol and prolactin is regulated downwards) and the content of each bile acid (lithocholic acid, sodium taurocholate and tauchenodeoxycholic acid) is obviously improved, the number of saccular follicles in polycystic lesions is obviously reduced, and the corpus luteum is increased, wherein the LR10 effect is obviously better than other strains.
In addition, LG08 has a relatively remarkable effect on alleviating polycystic ovary syndrome, but is slightly worse than LR10, but after being compounded with LR10, the effect is better than that of single strain LR10, probably because the two strains can mutually promote each other's growth and metabolism activities, so that a synergistic effect is achieved in terms of callback hormone level, alleviation of polycystic lesions and improvement of bile acid content in liver.
The applicant states that the present invention is illustrated by the above examples as a lactobacillus reuteri for the treatment of polycystic ovary syndrome and its use, but the present invention is not limited to, i.e. it is not meant to be necessarily dependent upon, the above examples for practice. It should be apparent to those skilled in the art that any modification of the present invention, equivalent substitution of raw materials for the product of the present invention, addition of auxiliary components, selection of specific modes, etc., falls within the scope of the present invention and the scope of disclosure.
The preferred embodiments of the present invention have been described in detail above, but the present invention is not limited to the specific details of the above embodiments, and various simple modifications can be made to the technical solution of the present invention within the scope of the technical concept of the present invention, and all the simple modifications belong to the protection scope of the present invention.
In addition, the specific features described in the above embodiments may be combined in any suitable manner, and in order to avoid unnecessary repetition, various possible combinations are not described further.
Claims (10)
1. The lactobacillus reuteri for treating polycystic ovary syndrome is characterized by specifically named lactobacillus reuteri (Lactobacillus reuteri) LR10, the preservation unit is China general microbiological culture Collection center (CGMCC) with the preservation number of CGMCC No.24409, the preservation date of 2022 is 2 and 21 days, and the preservation address of Beicheng-Kogyan North Xielu No.1 hospital No. 3.
2. The lactobacillus reuteri LR10 microbial agent is characterized by being prepared by a method comprising the following steps of: inoculating lactobacillus reuteri LR10 according to claim 1 into culture medium, and culturing at 35-40deg.C.
3. The lactobacillus reuteri LR10 inoculant of claim 2, wherein the medium comprises MRS medium.
4. A lactobacillus reuteri LR10 inoculant according to claim 2 or 3, wherein the incubation time is 18-24 hours;
preferably, the culturing further comprises centrifugation, and the thalli are collected;
preferably, the method further comprises mixing the bacterial cells with a protective agent, wherein the protective agent comprises glycerol.
5. The composite microbial inoculum is characterized by comprising lactobacillus reuteri LR10 and lactobacillus gasseri (Lactobacillus gasseri) LG08 as claimed in claim 1, wherein the preservation number of the lactobacillus gasseri LG08 is CGMCC No.16131, the preservation date is 2018, 7 and 18, and the preservation address is North Chen Silu No.1, 3 in the Chaoyang area of Beijing city.
6. The composite microbial agent according to claim 5, wherein the ratio of the viable count of lactobacillus reuteri LR10 to lactobacillus gasseri LG08 is (1-9): 1-3.
7. The composite microbial inoculant of claim 5 or 6, further comprising a protectant comprising glycerol.
8. Use of lactobacillus reuteri LR10 according to claim 1, a lactobacillus reuteri LR10 bacterial agent according to any of claims 2-4 or a complex bacterial agent according to any of claims 5-7 in the manufacture of a medicament for the treatment/alleviation of polycystic ovary syndrome.
9. Use of lactobacillus reuteri LR10 according to claim 1, a lactobacillus reuteri LR10 bacterial agent according to any of claims 2-4 or a complex bacterial agent according to any of claims 5-7 for the manufacture of a medicament for modulating hormonal disorders, wherein said hormone comprises any of testosterone, luteinizing hormone, progesterone, estradiol or a combination of at least two thereof.
10. Use of lactobacillus reuteri LR10 according to claim 1, a lactobacillus reuteri LR10 bacterial agent according to any of claims 2-4 or a complex bacterial agent according to any of claims 5-7 for the manufacture of a medicament for promoting bile acid secretion, wherein said bile acid comprises any of lithocholic acid, taurocholate or tauchenodeoxycholic acid or a combination of at least two thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310370659.5A CN116355804B (en) | 2023-04-10 | 2023-04-10 | Lactobacillus reuteri for treating polycystic ovary syndrome and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310370659.5A CN116355804B (en) | 2023-04-10 | 2023-04-10 | Lactobacillus reuteri for treating polycystic ovary syndrome and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116355804A true CN116355804A (en) | 2023-06-30 |
| CN116355804B CN116355804B (en) | 2023-11-21 |
Family
ID=86908005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310370659.5A Active CN116355804B (en) | 2023-04-10 | 2023-04-10 | Lactobacillus reuteri for treating polycystic ovary syndrome and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116355804B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115364126A (en) * | 2021-05-17 | 2022-11-22 | 上海交通大学医学院附属仁济医院 | Application of lactobacillus reuteri in preparation of medicine for treating polycystic ovarian syndrome |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110747146A (en) * | 2019-11-28 | 2020-02-04 | 江苏微康生物科技有限公司 | Lactobacillus gasseri LG08 with uric acid degradation effect and application thereof |
| CN114470008A (en) * | 2022-01-26 | 2022-05-13 | 佛山市第一人民医院 | Application of lactobacillus brevis or lactobacillus reuteri in preparation of product for treating premature ovarian failure |
| EP4000626A1 (en) * | 2020-11-16 | 2022-05-25 | concrete flowers GmbH | Pharmaceutical preparation |
| CN115364126A (en) * | 2021-05-17 | 2022-11-22 | 上海交通大学医学院附属仁济医院 | Application of lactobacillus reuteri in preparation of medicine for treating polycystic ovarian syndrome |
-
2023
- 2023-04-10 CN CN202310370659.5A patent/CN116355804B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110747146A (en) * | 2019-11-28 | 2020-02-04 | 江苏微康生物科技有限公司 | Lactobacillus gasseri LG08 with uric acid degradation effect and application thereof |
| EP4000626A1 (en) * | 2020-11-16 | 2022-05-25 | concrete flowers GmbH | Pharmaceutical preparation |
| CN115364126A (en) * | 2021-05-17 | 2022-11-22 | 上海交通大学医学院附属仁济医院 | Application of lactobacillus reuteri in preparation of medicine for treating polycystic ovarian syndrome |
| CN114470008A (en) * | 2022-01-26 | 2022-05-13 | 佛山市第一人民医院 | Application of lactobacillus brevis or lactobacillus reuteri in preparation of product for treating premature ovarian failure |
Non-Patent Citations (3)
| Title |
|---|
| SHANG LI ET AL.: ""Alleviation of Limosilactobacillus reuteri in polycystic ovary syndrome protects against circadian dysrhythmia-induced dyslipidemia via capric acid and GALR1 signaling"", 《NPJ BIOFILMS MICROBIOMES 》, vol. 9, no. 1, pages 1 - 18 * |
| THEOFILOS POUTAHIDIS ET AL.: ""Probiotic Microbes Sustain Youthful Serum Testosterone Levels and Testicular Size in Aging Mice"", 《PLOS ONE》, vol. 9, pages 1 - 12 * |
| 黄海敏等: ""肠道微生物与性激素相关疾病研究进展"", 《生物技术通报》, vol. 36, no. 2, pages 77 - 82 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115364126A (en) * | 2021-05-17 | 2022-11-22 | 上海交通大学医学院附属仁济医院 | Application of lactobacillus reuteri in preparation of medicine for treating polycystic ovarian syndrome |
| CN115364126B (en) * | 2021-05-17 | 2023-11-21 | 上海交通大学医学院附属仁济医院 | Application of lactobacillus reuteri in preparation of polycystic ovary syndrome treatment drug |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116355804B (en) | 2023-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3858977B1 (en) | Strain for preventing and treating metabolic diseases and use thereof | |
| EP4053262A1 (en) | Lactobacillus casei producing short-chain fatty acids, cultivation method therefor and application thereof | |
| CN114507621B (en) | Lactobacillus plantarum and application thereof in reducing uric acid, weight and inflammation | |
| CN114717147B (en) | Post-natal element prepared from lactobacillus rhamnosus and used for relieving fatty liver and obesity and application thereof | |
| KR20160138056A (en) | Butyric acid-producing microbe and use thereof | |
| CN116355804B (en) | Lactobacillus reuteri for treating polycystic ovary syndrome and application thereof | |
| Yi et al. | Lactobacillus plantarum CQPC02-fermented soybean milk improves loperamide-induced constipation in mice | |
| CN116445346B (en) | Lactobacillus reuteri for improving polycystic ovary syndrome and application thereof | |
| CN111213885A (en) | Probiotic composition with blood fat regulating effect and preparation method and application thereof | |
| CN115927045B (en) | Lactobacillus salivarius 069 with cholesterol reducing and liver injury relieving functions caused by hyperlipidemia and application thereof | |
| WO2021143621A1 (en) | Anaerostipes sp b2131 strain and use thereof in inflammatory bowel diseases | |
| KR20120055828A (en) | Lactobacillus acidophilus K-59, extracts from ginseng-fermented products using K-59 for improving insulin secretion and manufacturing method thereof | |
| CN109593678B (en) | Bifidobacterium longum YH295 and application thereof in preparing product for reducing abdominal obesity risk | |
| CN111228316B (en) | Composite probiotics for improving diabetes | |
| CN117025489B (en) | Bifidobacterium animalis subspecies VB315 and application thereof | |
| WO2022110281A1 (en) | Bifidobacterium bifidum i771, separation and purification method therefor, and application thereof | |
| US20210069267A1 (en) | Methods and Compositions for Treating or Preventing Gut Barrier Dysfunction | |
| JP7150451B2 (en) | Lactic acid fermented product | |
| CN110616167A (en) | Bifidobacterium capable of relieving atopic dermatitis and application thereof | |
| WO2021169627A1 (en) | Application of blautia sp b2132 strain in preventing and/or treating inflammatory bowel disease | |
| CN111481594B (en) | Plant fermentation product and application thereof in regulating gene expression amount and cardiovascular health care | |
| CN114617265A (en) | Application of inactivated lactobacillus casei IOB-P9 metagenesis powder in reducing blood sugar | |
| CN116574664A (en) | Application of bifidobacterium longum extracellular polysaccharide in promoting proliferation of lactic acid bacteria | |
| Yang et al. | Lactobacillus buchneri ameliorates obesity-related disorders induced by high-fat and high-cholesterol diet in mice | |
| CN115074277A (en) | Clostridium pralatanorum capable of relieving obesity and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |